Skip to main content
. Author manuscript; available in PMC: 2013 Jan 15.
Published in final edited form as: N Engl J Med. 2012 Mar 14;366(12):1079–1089. doi: 10.1056/NEJMoa1112304

Figure 2. Multivariate Risk Classification of Patients with Intermediate-Risk AML.

Figure 2

Kaplan–Meier estimates of overall survival are shown for the risk stratification of patients with intermediate-risk AML (with P values for the comparison of all curves). Among patients with wild-type FLT3-ITD (Panel A), there were three categories: patients with mutant TET2, ASXL1, PHF6, or MLL-PTD, who had a poor prognosis for overall survival; those with mutant IDH1 or IDH2 and mutant NPM1, who had a good prognosis for overall survival; and those with any other genotypes, who had an intermediate prognosis for survival. Among patients who were positive for FLT3-ITD mutations (Panel B), there were also three categories of patients: those with mutant TET2, DNMT3A, or MLL-PTD or trisomy 8 without mutant CEBPA, who had a poor prognosis for overall survival; those with mutant CEBPA, who had an intermediate prognosis for survival; and those with any other genotypes, who also had an intermediate prognosis for survival.

HHS Vulnerability Disclosure